CTIS2023-503969-36-00进行中（未招募）1 期
Safety, Tolerability and Efficacy of NPI-001 (AT-001) in Patients with Hereditary Cystatin C Amyloid Angiopathy (HCCAA) - 2023-503969-36-00
Arctic Therapeutics ehf.0 个研究点目标入组 25 人开始时间: 2023年5月15日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 65+（—）
- 性别
- All
入选标准
- •1.Patient is male or female, aged 12 or older, and of Icelandic ancestry (see section 5.1 Selection of Trial Population). Subjects 12-17 years old will only qualify for inclusion if the DSMB approves lowering the minimum age following review of at least 3 months of safety in adults., 2.Patient has been genotyped/sequenced and confirmed to carry the L68Q mutation in the cystatin C gene., 3.Patient is willing to have a baseline and follow up skin biopsies according to the schedule of assessments, for up to 12 months., 4.Patient is willing to have a baseline and follow up blood tests according to the schedule of assessments, for up to 12 months., 5.Patient is willing to undergo MRI evaluations of the brain., 6.Patient has provided informed consent for participation in trial, 7.Patient is willing and able to use contraception consistent with local regulations regarding the methods for participants in the clinical trial. Both female participants of childbearing potential and male participants able to father children must have (or have a partner who has) had a bilateral oophorectomy, hysterectomy or bilateral salpingectomy; must abstain from intercourse; or must agree to practice 2 acceptable methods of contraception throughout the course of the study and 4 weeks after the last visit. Acceptable methods of contraception include hormonal contraception (i.e., birth control pills, injected hormones, dermal patch or vaginal ring), intrauterine device, barrier methods (diaphragm, condom), tubal ligation, and vasectomy., 2.3.Patients with mild cognitive impairment with cognitive function to follow the study protocol.
排除标准
- •1.Patient does not have L68Q mutation, 10.Patient is taking medications known to affect or be affected by CYP enzymes or transporters will be excluded to avoid any inference, 2.Patient has clinically significant illness, mental or physical, that, in the opinion of the investigator, might confound the results of the study, pose additional risk to the patient by their participation, or prevent/impede the patient from completing the study., 3.Patient has known sensitivity to NAC, 4.Subject is not willing to cease NAC supplementation at least 2 weeks prior to study participation., 5.Patient is pregnant or breastfeeding., 6.Known or suspected excessive alcohol or drug abuse, 7.There is any concern by the investigator regarding the patient’s safety, compliance, or suitability with respect to his/her participation in the study., 8.Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 14 days, whichever is longer, 1.2.Patients with moderate to severe cognitive impairment.
研究者
相似试验
招募中
1 期
Safety, Tolerability and Efficacy of NPI-001 (AT-001) in Patients with Hereditary Cystatin C Amyloid Angiopathy (HCCAA)Hereditary Cystatin C Amyloid Angiopathy (HCCAA)MedDRA version: 21.1Level: PTClassification code: 10068044Term: Cerebral amyloid angiopathy Class: 100000004852CTIS2023-503969-36-01Arctic Therapeutics ehf.25
已完成
1 期
NI-0401 in Patients With Acute Renal Allograft RejectionAcute Renal Transplant RejectionNCT00805909Light Chain Bioscience - Novimmune SA12
撤回
1 期
Safety and tolerability of the Traditional Chinese Medicine Formulation GOPAC in patients with advanced malignancyAdvanced malignancy (palliative)Cancer - Other cancer typesACTRN12609000652279Sydney South West Area Health Service70
已完成
不适用
The evaluation of the efficacy and the safety of TSUMURA Tokishakuyakusan Extract Granules for Ethical Use on endometriosis patients with dysmenorrheaEndometriosisJPRN-UMIN000017908Tottori University Faculty of Medicine15
招募中
2 期
Clinical study on Nutraceutical Tablet in sleep problemCTRI/2024/05/066597SciTech Specialties Pvt. Ltd.